

## Daily evidence digest

5 May 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Remdesivir for hospitalised COVID-19 patients, Omicron BA.4 and BA.5 lineages, BA.2.12.1

#### Peer reviewed journals featured:

- The WHO solidarity randomised trial on remdesivir and three other drugs for hospitalised COVID-19 patients [here](#) and associated commentary [here](#)
- Observational studies on:
  - Maternal and perinatal outcomes associated with SARS-CoV-2 infection in pregnancy [here](#)
  - Relationship between social activity and loneliness in depressed people over 14-days of physical isolation during COVID-19 in Australia [here](#)
  - Long-term mortality following SARS-CoV-2 infection in Estonia [here](#)
- Commentary on sustainable development goals after the pandemic [here](#)

#### Pre-peer review articles featured:

- New BA.4 and BA.5 lineages of Omicron identified in South Africa [here](#)
- BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection [here](#)
- Describing COVID-19 patients in the first two months of Paxlovid (nirmatrelvir/ritonavir) initiation in Israel [here](#)
- Comparison of COVID-19 outcomes between patients infected with Omicron and Delta variants [here](#)

[Click here](#) to subscribe to the daily evidence digest.

#### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).